In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008

Executive Summary

Highlights from the Q2 2008 review of pharmaceutical and biotechnology dealmaking: Despite the dearth in biopharmaceutical financings in the quarter (total money raised was just $2 billion) acquisitions thrived with total M&A volume of $11.8 billion. And biopharma alliance activity reached $2.7 billion in potential deal value during 2008's second quarter with only a handful more deals than the first quarter, but a 43% increase in dollar volume.
Advertisement

Related Content

Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Sirtris Satisfies GSK's M&A Appetite
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Esperion, Again: Pfizer's First Spin-Out's Familiar Look
Esperion, Again: Pfizer's First Spin-Out's Familiar Look
Takeda/ Millennium: The Price is Right
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
A Recipe for Acquisition: the Esperion Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel